Immunophenotypic findings in acute myeloid leukemia with FLT3 internal tandem duplication

被引:0
|
作者
Muñoz, L [1 ]
Aventín, A [1 ]
Villamor, N [1 ]
Juncà, J [1 ]
Acebedo, G [1 ]
Domingo, A [1 ]
Rozman, M [1 ]
Torres, JP [1 ]
Tormo, M [1 ]
Nomdedéu, JF [1 ]
机构
[1] Hosp Santa Creu & Sant Pau, Hematol Lab, Barcelona 08025, Spain
关键词
FLT3 internal tandem duplication; acute myeloid leukemia; immunophenotype; karyotype; minimal residual disease;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives. The biological characteristics and prognostic significance of the internal tandem duplication of the FLT3 (FLT3/ITD) were investigated in a series of de novo acute myeloid leukemia (AML) patients. One hundred and fifty-six adult patients with AML were included in the study. FLT3/ITD was detected in 41 (26%) patients (FLT3/ITD+). Design and Methods. The main differences observed between the groups with and without FLT3/ITD: a higher leukocyte count, a raised percentage of a normal karyotype and a more frequent M5 FAB diagnosis in the FLT3/ITD+ patients. As regards the immunophenotypic characteristics the FLT3/ITD+ group very often expressed monocytic markers (CD36 and CD11b) and less commonly immature markers (CD34 and CD117). A promyelocytic-like immunophenotype pattern was also detected in a minority of these patients (4/36). Results. The FLT3/ITD+ patients had a shorter overall survival. a shorter event-free survival and a higher probability of relapse. Minimal residual disease (MRD) was investigated in the FLT3/ITD+ patients using flow cytometry. This technique had a sensitivity of 62% and a specificity of 83% in relapse prediction. Minimal residual disease analysis was hampered by the low number of patients with detectable aberrant immunophenotype. Interpretation and Conclusions. A high frequency of changes in the phenotype and/or genotype pattern between diagnosis and relapse was detected (5/6). FLT3/ITD is a frequent molecular lesion in de novo adult AML and seems to be associated with momnocytic differentaition, a high leukocyte count and a poor prognosis. Immunophenotype and genotype patterns observed at relapse suggest that the FLT3/ITD+ blasts may be genetically unstable and prone to clonal evolution. FLT3/ITD may not be a suitable target for minimal residual disease studies. (C) 2003, Ferrata Storti Foundation.
引用
收藏
页码:637 / 645
页数:9
相关论文
共 50 条
  • [41] Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3
    Levis, Mark J.
    Hamadani, Mehdi
    Logan, Brent
    Jones, Richard J.
    Singh, Anurag K.
    Litzow, Mark
    Wingard, John R.
    Papadopoulos, Esperanza B.
    Perl, Alexander E.
    Soiffer, Robert J.
    Ustun, Celalettin
    Ueda Oshima, Masumi
    Uy, Geoffrey L.
    Waller, Edmund K.
    Vasu, Sumithra
    Solh, Melhem
    Mishra, Asmita
    Muffly, Lori
    Kim, Hee-Je
    Mikesch, Jan-Henrik
    Najima, Yuho
    Onozawa, Masahiro
    Thomson, Kirsty
    Nagler, Arnon
    Wei, Andrew H.
    Marcucci, Guido
    Geller, Nancy L.
    Hasabou, Nahla
    Delgado, David
    Rosales, Matt
    Hill, Jason
    Gill, Stanley C.
    Nuthethi, Rishita
    King, Denise
    Wittsack, Heather
    Mendizabal, Adam
    Devine, Steven M.
    Horowitz, Mary M.
    Chen, Yi-Bin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (15) : 1766 - 1775
  • [42] Mutation of FLT3 gene in acute myeloid leukemia with normal cytogenetics and its association with clinical and immunophenotypic features
    Pradeep S. Chauhan
    Bharat Bhushan
    Ashwani K. Mishra
    Laishram C. Singh
    Sumita Saluja
    Saurabh Verma
    Dipendra K. Gupta
    Vishakha Mittal
    Sumita Chaudhry
    Sujala Kapur
    Medical Oncology, 2011, 28 : 544 - 551
  • [43] Mutation of FLT3 gene in acute myeloid leukemia with normal cytogenetics and its association with clinical and immunophenotypic features
    Chauhan, Pradeep S.
    Bhushan, Bharat
    Mishra, Ashwani K.
    Singh, Laishram C.
    Saluja, Sumita
    Verma, Saurabh
    Gupta, Dipendra K.
    Mittal, Vishakha
    Chaudhry, Sumita
    Kapur, Sujala
    MEDICAL ONCOLOGY, 2011, 28 (02) : 544 - 551
  • [45] Implications of FLT3 Mutations in the Therapy of Acute Myeloid Leukemia
    Mattison, Ryan J.
    Ostler, Kelly R.
    Locke, Frederick L.
    Godley, Lucy A.
    REVIEWS ON RECENT CLINICAL TRIALS, 2007, 2 (02) : 135 - 141
  • [46] Effect of FLT3 Ligand on Survival and Disease Phenotype in Murine Models Harboring a FLT3 Internal Tandem Duplication Mutation
    Bailey, Emily J.
    Duffield, Amy S.
    Greenblatt, Sarah M.
    Aplan, Peter D.
    Small, Donald
    COMPARATIVE MEDICINE, 2013, 63 (03) : 218 - 226
  • [47] Recent advances in FLT3 inhibitors for acute myeloid leukemia
    Tong, Lexian
    Li, Xuemei
    Hu, Yongzhou
    Liu, Tao
    FUTURE MEDICINAL CHEMISTRY, 2020, 12 (10) : 961 - 981
  • [48] FLT3 inhibitors in acute myeloid leukemia: Current and future
    Thomas, Christan M.
    Campbell, Peter
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (01) : 163 - 171
  • [49] Will FLT3 inhibitors fulfill their promise in acute myeloid leukemia?
    Pratz, Keith W.
    Luger, Selina M.
    CURRENT OPINION IN HEMATOLOGY, 2014, 21 (02) : 72 - 78
  • [50] The importance of FLT3 mutational analysis in acute myeloid leukemia
    Patnaik, Mrinal M.
    LEUKEMIA & LYMPHOMA, 2018, 59 (10) : 2273 - 2286